523 related articles for article (PubMed ID: 22244043)
21. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
22. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis.
Di Taranto MD; D'Agostino MN; Fortunato G
Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):979-87. PubMed ID: 26165249
[TBL] [Abstract][Full Text] [Related]
25. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.
Radovica-Spalvina I; Latkovskis G; Silamikelis I; Fridmanis D; Elbere I; Ventins K; Ozola G; Erglis A; Klovins J
BMC Med Genet; 2015 Sep; 16():86. PubMed ID: 26415676
[TBL] [Abstract][Full Text] [Related]
26. An APEX-based genotyping microarray for the screening of 168 mutations associated with familial hypercholesterolemia.
Dušková L; Kopečková L; Jansová E; Tichý L; Freiberger T; Zapletalová P; Soška V; Ravčuková B; Fajkusová L
Atherosclerosis; 2011 May; 216(1):139-45. PubMed ID: 21310417
[TBL] [Abstract][Full Text] [Related]
27. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
[TBL] [Abstract][Full Text] [Related]
29. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing.
Maglio C; Mancina RM; Motta BM; Stef M; Pirazzi C; Palacios L; Askaryar N; Borén J; Wiklund O; Romeo S
J Intern Med; 2014 Oct; 276(4):396-403. PubMed ID: 24785115
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
[TBL] [Abstract][Full Text] [Related]
31. LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.
Snozek CL; Lagerstedt SA; Khoo TK; Rubenfire M; Isley WL; Train LJ; Baudhuin LM
Eur J Hum Genet; 2009 Jan; 17(1):85-90. PubMed ID: 18648394
[TBL] [Abstract][Full Text] [Related]
32. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Tada H; Nakanishi C; Mori M; Yamagishi M; Inazu A; Koizumi J;
Atherosclerosis; 2011 Feb; 214(2):404-7. PubMed ID: 21146822
[TBL] [Abstract][Full Text] [Related]
34. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic.
Tosi I; Toledo-Leiva P; Neuwirth C; Naoumova RP; Soutar AK
Atherosclerosis; 2007 Sep; 194(1):102-11. PubMed ID: 17094996
[TBL] [Abstract][Full Text] [Related]
35. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
36. The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations.
Tichý L; Freiberger T; Zapletalová P; Soška V; Ravčuková B; Fajkusová L
Atherosclerosis; 2012 Aug; 223(2):401-8. PubMed ID: 22698793
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
Pirillo A; Garlaschelli K; Arca M; Averna M; Bertolini S; Calandra S; Tarugi P; Catapano AL;
Atheroscler Suppl; 2017 Oct; 29():17-24. PubMed ID: 28965616
[TBL] [Abstract][Full Text] [Related]
38. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
Miserez AR; Martin FJ; Spirk D
Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060
[TBL] [Abstract][Full Text] [Related]
39. Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco.
Chater R; Aït Chihab K; Rabès JP; Varret M; Chabraoui L; El Jahiri Y; Adlouni A; Boileau C; Kettani A; El Messal M
Clin Chim Acta; 2006 Nov; 373(1-2):62-9. PubMed ID: 16806138
[TBL] [Abstract][Full Text] [Related]
40. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
